Humacyte, Inc., was incorporated in Delaware on July 1, 2020. The company is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissue, advanced tissue structures and organ systems with the goal of improving the lives of patients and transforming medical practice. The company is utilizing a novel, scalable technology platform to develop proprietary bioengineered cell-free human tissue for the treatment of diseases and conditions at a range of anatomical locations across multiple therapeutic areas. 

Expected P&L on Expiry

Key Stats

Pricing Model

About HUMA20260618P1